Avacta to present promising new data from Affimer and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

5 October 2023

Avacta Group plc

(“Avacta” or the “Group” or the “Company”)

Avacta to present promising new data from Affimer and pre|CISION^TM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

• AVA3996: FAP-α-activated proteasome inhibitor from pre|CISION^TM platform concentrates proteasome inhibitor payload in the tumour, increasing the therapeutic index of this class of drugs
• AVA032: anti-PD-L1 Affimer fused to IL-15 demonstrates encouraging in vitro and in vivo efficacy

Avacta Group plc (AIM: AVCT), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, today announces that it will be presenting two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place on 11-15 October 2023 in Boston Massachusetts.

Details of the poster presentations are as follows:

Abstract title:  AVA3996, a novel pre|CISION medicine, targets a warhead to the tumor microenvironment via Fibroblast Activation Protein (“FAP”) mediated cleavage to elicit tumor cell kill

Poster number:                                C169
Session:                                             Poster Session C                             
Session date and time:                  Saturday, October 14 | 12:30 pm-4:00 pm
Session location:                             Level 2, Exhibit Hall D

Abstract title: A novel, tumor-targeted immunocytokine comprising an anti-PD-L1 Affimer fused to IL-15 exhibits potent anti-tumor activity

Poster number:                                A077